# Fecal Molecular Susceptibility-guided Hp First-line Therapy

> **NCT07405684** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 544 (estimated)

## Conditions studied

- HELICOBACTER PYLORI INFECTIONS

## Interventions

- **DRUG:** 7-day fecal molecular susceptibility-guided therapy
- **DRUG:** 14-day fecal molecular susceptibility-guided therapy

## Key facts

- **NCT ID:** NCT07405684
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 544 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07405684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07405684, "Fecal Molecular Susceptibility-guided Hp First-line Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07405684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*